ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 092,11
-0,61%
Dow Jones
39 671,04
-0,51%
DAX
18 680,20
-0,25%
Brent Oil
81,345
-0,23%
Bitcoin
69 396,03
0,42%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Journey Medical Corporation (DERM)

  7. Journey Medical Corporation (DERM) Actualités

DERM

Journey Medical (DERM)

Journey Medical Corporation
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:DERM
DateHeureSourceTitreSymboleSociété
15/05/202422h01GlobeNewswire Inc.Journey Medical Corporation to Participate in the Alliance Global Partners’ (A.G.P.) Virtual Healthcare Company ShowcaseNASDAQ:DERMJourney Medical Corporation
14/05/202422h46Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:DERMJourney Medical Corporation
13/05/202422h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:DERMJourney Medical Corporation
13/05/202422h01GlobeNewswire Inc.Journey Medical Corporation Reports First Quarter 2024 Financial Results and Recent Corporate HighlightsNASDAQ:DERMJourney Medical Corporation
07/05/202414h30GlobeNewswire Inc.Journey Medical Corporation to Announce First Quarter 2024 Financial Results on May 13, 2024NASDAQ:DERMJourney Medical Corporation
01/05/202422h01GlobeNewswire Inc.Journey Medical Corporation Appoints Joseph Benesch as Chief Financial OfficerNASDAQ:DERMJourney Medical Corporation
25/04/202414h30GlobeNewswire Inc.Journey Medical Corporation to Present at the Planet MicroCap Showcase: Vegas 2024NASDAQ:DERMJourney Medical Corporation
21/03/202421h01GlobeNewswire Inc.Journey Medical Corporation Reports Full-Year 2023 Financial Results and Recent Corporate HighlightsNASDAQ:DERMJourney Medical Corporation
18/03/202413h30GlobeNewswire Inc.Journey Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of RosaceaNASDAQ:DERMJourney Medical Corporation
15/03/202413h30GlobeNewswire Inc.Journey Medical Corporation to Announce Year End 2023 Financial Results on March 21, 2024NASDAQ:DERMJourney Medical Corporation
13/03/202413h30GlobeNewswire Inc.Journey Medical Corporation to Participate in the 36th Annual ROTH ConferenceNASDAQ:DERMJourney Medical Corporation
11/03/202413h30GlobeNewswire Inc.Journey Medical Corporation Announces Presentation of Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adults at 2024 AAD Annual MeetingNASDAQ:DERMJourney Medical Corporation
23/02/202423h54Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DERMJourney Medical Corporation
05/01/202414h30GlobeNewswire Inc.Journey Medical Corporation Submits New Drug Application to FDA for DFD-29 to Treat RosaceaNASDAQ:DERMJourney Medical Corporation
02/01/202422h05GlobeNewswire Inc.Journey Medical Corporation Secures Credit Facility with SWK Holdings for up to $20 MillionNASDAQ:DERMJourney Medical Corporation
15/12/202322h46Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:DERMJourney Medical Corporation
06/12/202314h00GlobeNewswire Inc.Journey Medical Corporation Announces Successful Completion of Pre-NDA Meeting with the FDA for DFD-29 to Treat RosaceaNASDAQ:DERMJourney Medical Corporation
07/11/202322h01GlobeNewswire Inc.Journey Medical Corporation Reports Third Quarter 2023 Financial Results and Recent Corporate HighlightsNASDAQ:DERMJourney Medical Corporation
31/10/202313h30GlobeNewswire Inc.Journey Medical Corporation to Announce Third Quarter 2023 Financial Results on November 7, 2023NASDAQ:DERMJourney Medical Corporation
20/10/202314h30GlobeNewswire Inc.Journey Medical Corporation Announces Data from Bioavailability Study of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) vs. Solodyn® (Minocycline Hydrochloride Extended-Release Tablets, 105 mg)NASDAQ:DERMJourney Medical Corporation
06/09/202314h00GlobeNewswire Inc.Journey Medical Corporation Enters into an Exclusive License Agreement with Maruho Co., Ltd. for Qbrexza® in South Korea and Other Asian NationsNASDAQ:DERMJourney Medical Corporation
14/08/202322h01GlobeNewswire Inc.Fortress Biotech Reports Second Quarter 2023 Financial Results and Recent Corporate HighlightsNASDAQ:DERMJourney Medical Corporation
08/08/202322h01GlobeNewswire Inc.Journey Medical Corporation Reports Second Quarter 2023 Financial Results and Recent Corporate HighlightsNASDAQ:DERMJourney Medical Corporation
02/08/202322h01GlobeNewswire Inc.Journey Medical Corporation to Announce Second Quarter 2023 Financial Results on August 8, 2023NASDAQ:DERMJourney Medical Corporation
19/07/202314h30GlobeNewswire Inc.Journey Medical Corporation to Announce Second Quarter 2023 Financial Results the Week of August 7, 2023NASDAQ:DERMJourney Medical Corporation
11/07/202314h30GlobeNewswire Inc.Journey Medical Corporation Announces Positive Topline Results from its Two Phase 3 Clinical Trials (MVOR-1 and MVOR-2) Evaluating DFD-29 for the Treatment of Papulopustular Rosacea in AdultsNASDAQ:DERMJourney Medical Corporation
03/07/202314h00GlobeNewswire Inc.Journey Medical Corporation Expects Topline Results from the Phase 3 Clinical Trials (MVOR-1 and MVOR-2) Evaluating DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) for the Treatment of Papulopustular Rosacea to be Announced Week of JulyNASDAQ:DERMJourney Medical Corporation
23/06/202322h06Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:DERMJourney Medical Corporation
13/06/202314h30GlobeNewswire Inc.Journey Medical Corporation Announces Positive Topline Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adult SubjectsNASDAQ:DERMJourney Medical Corporation
22/05/202322h01GlobeNewswire Inc.Journey Medical Corporation Reports First Quarter 2023 Financial Results and Recent Corporate HighlightsNASDAQ:DERMJourney Medical Corporation
 Showing the most relevant articles for your search:NASDAQ:DERM

Dernières Valeurs Consultées

NASDAQ
FTLEWX
Interest Rate Hedge Port...
NASDAQ
RTIX
RTI Surgical
BIT
P1ZP46
NLBNPIT1ZP46 20240620 4900
LSE
92YT
Municplty 39
BIT
P1ZDO3
NLBNPIT1ZDO3 20240621 190
ASX
OOKO
Ookami
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés